Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential
Mirum Pharmaceuticals' promising pipeline and strong financials make it an attractive buy in the competitive PBC space. Click ...
Arvinas' Vepdegestrant: Why The Data May Not Hold Up
Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...